FDA Approves C1 Inhibitor Protein for the Prevention of Hereditary Angioedema Attacks
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves C1 Inhibitor Protein for the Prevention of Hereditary Angioedema Attacks

ROCKVILLE, Md -- October 10, 2008 -- The US Food and Drug Administration (FDA) has approved a C1 inhibitor human protein [Cinryze] for the prevention of attacks in patients with hereditary angioedema (HAE).

"[The inhibitor] should greatly enhance treatment options for those with hereditary angioedema and potentially save lives," said Jesse Goodman, MD, FDA's Center for Biologics Evaluation and Research, Rockville, Maryland.

In clinical trials, the product was effective in preventing or decreasing the frequency of attacks in most but not all patients with HAE. Adverse reactions reported in the study were considered mild or moderate in severity.

SOURCE: US Food and Drug Administration

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities